Literature DB >> 705695

Acquired inhibitors of factor V.

D I Feinstein.   

Abstract

The clinical and laboratory data on the 12 patients with an acquired inhibitor to factor V have been reviewed. The degree of clinical bleeding in these patients varied from none to severe, and in most patients the inhibitor was transient. The combination of a markedly prolonged partial thromboplastin time and Quick prothrombin time and failure of normal plasma to correct these tests, in the presence of a normal thrombin and prothrombin and proconvertin time, seems to be pathognomonic for a factor V inhibitor. The inhibitors have physicochemical properties of immunoglobulins and a few have been characterized as polyclonal IgG antibodies or a mixture of IgM and IgG antibodies. The etiology and pathophysiologic mechanism of their development is unknown, but there seems to be a close relationship to major surgery. When tested with inhibitor plasma, the plasmas from 9 patients with hereditary factor V deficiency from 7 unrelated families did not contain factor V antibody-neutralizing material.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 705695

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

Review 2.  Immunologically generated circulating anticoagulants in humans.

Authors:  R L Edwards; C J Wakem
Journal:  Surv Immunol Res       Date:  1984

3.  Isolation and study of an acquired inhibitor of human coagulation factor V.

Authors:  M E Nesheim; W L Nichols; T L Cole; J G Houston; R B Schenk; K G Mann; E J Bowie
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

4.  Acquired Inhibitors to Multiple Coagulation Factors (V, IX, and XII) Identified in a Unique Patient with Hepatocellular Carcinoma.

Authors:  Osamu Imataki; Takeshi Arai; Makiko Uemura
Journal:  Intern Med       Date:  2017-05-15       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.